- Home
- AVTX vs FSEA Comparison
AVTX vs FSEA Comparison
Compare AVTX & FSEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- FSEA
- Stock Information
- Founded
- AVTX 2011
- FSEA 1890
- Country
- AVTX United States
- FSEA United States
- Employees
- AVTX N/A
- FSEA N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- FSEA Savings Institutions
- Sector
- AVTX Health Care
- FSEA Finance
- Exchange
- AVTX Nasdaq
- FSEA Nasdaq
- Market Cap
- AVTX 57.4M
- FSEA 53.3M
- IPO Year
- AVTX 2015
- FSEA N/A
- Fundamental
- Price
- AVTX $4.73
- FSEA $11.31
- Analyst Decision
- AVTX Strong Buy
- FSEA
- Analyst Count
- AVTX 7
- FSEA 0
- Target Price
- AVTX $31.00
- FSEA N/A
- AVG Volume (30 Days)
- AVTX 89.2K
- FSEA 6.0K
- Earning Date
- AVTX 08-11-2025
- FSEA 08-08-2025
- Dividend Yield
- AVTX N/A
- FSEA N/A
- EPS Growth
- AVTX N/A
- FSEA N/A
- EPS
- AVTX N/A
- FSEA 0.00
- Revenue
- AVTX $441,000.00
- FSEA $16,196,000.00
- Revenue This Year
- AVTX N/A
- FSEA N/A
- Revenue Next Year
- AVTX N/A
- FSEA N/A
- P/E Ratio
- AVTX $0.69
- FSEA $1,381.37
- Revenue Growth
- AVTX N/A
- FSEA 97.61
- 52 Week Low
- AVTX $3.39
- FSEA $8.60
- 52 Week High
- AVTX $16.00
- FSEA $11.80
- Technical
- Relative Strength Index (RSI)
- AVTX 57.87
- FSEA 51.70
- Support Level
- AVTX $4.46
- FSEA $11.00
- Resistance Level
- AVTX $4.90
- FSEA $11.33
- Average True Range (ATR)
- AVTX 0.37
- FSEA 0.17
- MACD
- AVTX 0.09
- FSEA -0.01
- Stochastic Oscillator
- AVTX 88.61
- FSEA 60.00
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.